News and Trends 7 Sep 2022 Alzinova announces new positive safety review for Alzheimer’s study Alzinova AB says a second external safety review has been carried out of its clinical phase 1b study. This resulted in a positive assessment to continue the study as planned. Behind the review is an independent expert group, Data and Safety Monitoring Board (DSMB), which continuously reviews the study. Based on the patients included in […] September 7, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Lytix Biopharma expanding advanced melanoma study to Europe Lytix Biopharma, a Norwegian immuno-oncology company, has received regulatory approval from European authorities to start its ATLAS-IT-05 study in three European countries. ATLAS-IT-05 is a phase II combination study evaluating LTX-315 and pembrolizumab in patients with advanced melanoma. The study was initiated at MD Anderson Cancer Center in 2021 and is currently ongoing in the […] September 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Ionis presents positive study results at International Symposium on amyloidosis Ionis Pharmaceuticals, Inc. has presented positive results from a planned 35-week interim analysis of the phase 3 NEURO-TTRansform study of Ionis and AstraZeneca’s eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). In the study, eplontersen demonstrated a statistically significant and clinically meaningful change from baseline for its co-primary and secondary efficacy endpoints compared to […] September 7, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Could COVID vaccine boosters become obsolete? A team of researchers at Tel Aviv University in Israel has demonstrated that antibodies isolated from the immune system of recovered COVID-19 patients are effective in neutralizing all known strains of the virus, including the Delta and the Omicron variants. According to the researchers, this discovery may eliminate the need for repeated booster vaccinations and […] September 7, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 TikoMed drug inhibits infection of human cells by dengue, zika and yellow fever viruses TikoMed has announced the inclusion in bioRxiv of an in vitro study examining the ability of the company’s lead drug candidate ILB to inhibit infection of human cells by four serotypes of dengue virus (DENV1-4), two strains of zika virus (African and Asian) and yellow fever virus (vaccine strain YF17D) assessed by immunofluorescence of viral […] September 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 6 Sep 2022 Meeting tech transfer challenges when manufacturing new biopharmaceuticals With increasingly complex therapeutics arriving almost monthly, efficient technology transfer between biopharma and manufacturers is more important than ever. Ken Forman, senior director of product strategy at IDBS, explains how good digital strategies can avoid common pitfalls in the tech transfer process. Biopharmaceutical lifecycle management (BPLM) is the key to delivering novel therapies and lifesaving […] September 6, 2022 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 Lonza and Touchlight collaboration will expands customer’s access to DNA Manufacturing partner, Lonza, has today (September 6) announced a collaboration with Touchlight, a biotech company that works with enzymatic DNA production enabling genetic medicine. Through this collaboration, Lonza says it will have the ability to expand it end-to-end offering for mRNA manufacturing with an additional source of DNA raw material. This material comes from Touchlight’s […] September 6, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 More companies enter BioInnovation Institute Venture Lab program Nine ventures and two projects have become the latest addition to The BioInnovation Institute’s (BII) Venture Lab acceleration program for early-stage companies. BioInnovation Institute is an international commercial non-profit foundation based in Denmark, which incubates and accelerates life science research. The cohort consists of nine ventures plus two corporate-sponsored innovation projects from Novo Nordisk – […] September 6, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 Finnish researchers use machine learning to unlock clinical cancer samples’ genomic code A new paper from the University of Helsinki, published in Nature Communications, suggests a method for accurately analyzing genomics data in archival cancer biopsies. The tool uses machine learning methods to correct damaged DNA and unveil the true mutation processes in tumor samples. This helps to unlock medicine values in millions of archival cancer samples. […] September 6, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 IRLAB’s partner Ipsen starts mesdopetam clinical studies IRLAB Therapeutics AB, a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, says its partner, Ipsen, has initiated clinical studies with drug candidate mesdopetam in accordance with its development plan. These are standard clinical pharmacokinetic studies that will run in parallel to the phase IIb study with […] September 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 Synaffix and Emergence in $360M technology platform deal to develop ADCs Dutch biotech Synaffix B.V. and German Emergence Therapeutics announced today (September 6) they have entered into a licensing agreement of up to $360 million. The agreement will provide Emergence access on a target-specific basis to Synaffix’s antibody drug conjugate (ADC) technologies made up of Glycoconnect, HydraSpace and SYNtecan E linker payload. Under the terms of […] September 6, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 Forsea Foods creates eel meat using patented organoid technology Cell cultured seafood produced with the same nutrients and texture has been developed through patented organoid technology. Previously used in developmental biology, medicine and research, organoids are stem cell-derived, three-dimensional tissue structures that, when used in cell-cultured seafood products, require only a minimal amount of growth factors. Forsea Foods Ltd. has announced it is beginning […] September 6, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email